We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 09, 2020

Association of PIK3CA Mutation With Prognosis and PAM50 Subtype in Early HER2+ Breast Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients With Early HER2+ Breast Cancer: Association With Prognosis and Integration With PAM50 Subtype
Clin. Cancer Res 2020 Aug 25;[EPub Ahead of Print], V Guarneri, MV Dieci, G Bisagni, AA Brandes, A Frassoldati, L Cavanna, A Musolino, F Giotta, A Rimanti, O Garrone, E Bertone, K Cagossi, O Nanni, F Piacentini, E Orvieto, G Griguolo, M Curtarello, L Urso, L Paré, N Chic, R D'Amico, A Prat, P Conte

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading